US Patent
US8642079 — Solid formulations of ospemifene
Formulation · Assigned to Hormos Medical Corp · Expires 2028-07-09 · 2y remaining
Vulnerability score
60/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects solid formulations of ospemifene, specifically granulates containing the active compound and intra-granular excipients.
USPTO Abstract
This invention relates to a solid drug formulation comprising granulates containing a therapeutically active compound of the formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, in combination with one or more intra-granular excipients.
Drugs covered by this patent
- Osphena (OSPEMIFENE) · Duchesnay
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.